1. Scrip
  2. >>Focus On Asia

BIO Korea 2016: SillaJen On Maximizing Value Of Pexa-Vec

 
• By Jung Won Shin

South Korea's SillaJen, which has ambitions to launch its oncolytic virus-based immunotherapy Pexa-Vec in global markets in the next few years, has unveiled progress of its global Phase III study and the company's global strategy during the recent BIO Korea 2016 in Seoul.

SEOUL - SillaJen Inc., which has just begun a global Phase III study of its oncolytic virus-based immunotherapy Pexa-Vec for hepatocellular carcinoma (HCC), aims to retain rights in some regions until as late as possible in order to maximize the value of the project.

Pexa-Vec (JX-594, pexastimogene devacirepvec) is the most advanced product candidate from the private South Korean clinical-stage biotherapeutics firm’s proprietary SOLVE...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By Vibha Ravi

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

Korea Q2 Roundup: Global Sales, License Income Boost Yuhan, GC

 
• By Jung Won Shin

Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

More from Scrip

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 
• By Jessica Merrill

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.